DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Escitalopram Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
According to the publisher’s market research, as a result of the impact of COVID-19 and the decreasing average price, the sales value of China’s escitalopram market in 2020 declined to approximately CNY329 million (USD50.6 million), with a CAGR of about -1.9% from 2016 to 2020.
Since H. Lundbeck A/S’s Lexapro is more expensive than generic drugs in the Chinese market, its market share has been declining, with a market share of around 66% in 2020 and is expected to continue to decline from 2021 to 2025. Companies with a relatively large market share of escitalopram in China include Sichuan Kelun Pharmaceutical, Jewim Pharmaceutical, Hunan Dongting Pharmaceutical and Jinhua CONBA.
The publisher expects that the number of depression patients in China will keep growing in the future due to increasing stresses of everyday life and changing interpersonal relationships resulted from factors like national economic development and rising urbanization. Suffering from depression is unfortunate, but if timely treatment is given, patients are able to return to normal life and work.
According to the publisher’s prediction, thanks to the development of China’s economy and the transformation of social attitudes, people will gradually be aware of the hazards of depression and more patients will be willing to seek medical treatment as well as take antidepressant medication. From 2021 to 2025, it is likely to see a recovery increase in the market size of escitalopram in China.
Topics Covered:
- Impact of COVID-19 on China’s Escitalopram Market
- Development Environment of Escitalopram in China
- Sales Volume of Escitalopram in China
- Sales Volume and Value of Escitalopram in China by Region
- Major Escitalopram Manufacturers in China and Their Market Shares
- Sales Price of Escitalopram in China
- Major Escitalopram Producers in China
- Prospects of China’s Escitalopram Market, 2021-2025
Key Topics Covered:
1 Relevant Concepts of Escitalopram
1.1 Indications of Escitalopram
1.2 Development of China’s Escitalopram Market
1.3 Governmental Approval of Escitalopram in China
1.4 The Impact of COVID-19 on China’s Escitalopram Market
2 Sales of Escitalopram in China, 2016-2020
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Escitalopram in China by Dosage Form, 2016-2020
2.3.1 Tablets
2.3.2 Other Dosage Forms
3 Analysis of Major Escitalopram Manufacturers in China, 2020
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 H. Lundbeck A/S
3.2.1 Company Profile
3.2.2 Sales of Escitalopram in China
3.3 Sichuan Kelun Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 Sales of Escitalopram in China
3.4 Jewim Pharmaceutical (Shandong) Co., Ltd.
3.5 Hunan Dongting Pharmaceutical Co., Ltd.
3.6 Zhejiang Jinhua CONBA Bio-pharm. Co., Ltd.
4 Sales Price of Escitalopram of Different Companies in China, 2020-2021
4.1 H. Lundbeck A/S (Lexapro)
4.2 Sichuan Kelun Pharmaceutical Co., Ltd. (BaiLuoTe)
4.3 Jewim Pharmaceutical (Shandong) Co., Ltd. (Baishike)
4.4 Hunan Dongting Pharmaceutical Co., Ltd. (QiCheng)
4.5 Zhejiang Jinhua CONBA Bio-pharm. Co., Ltd. (TaiQi)
5 Prospects of China’s Escitalopram Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
Companies Mentioned
- Beijing Sihuan Pharmaceutical Co., Ltd. (Jieao)
- HPGC Bioengineering (Ruishi)
For more information about this report visit https://www.researchandmarkets.com/r/fzdgy8
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900